Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Future of ctDNA in breast cancer management

Michail Ignatiadis • 25 Nov 2021
SABCS 2021
Breast Cancer

Michail Ignatiadis, MD, PhD, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium, explores the future of circulating tumor DNA (ctDNA) and its role in the treatment and management of cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Disclosures

Novartis, Invited Speaker and Advisory Board, Personal

Seattle Genetics, Other, Personal,

Independent monitoring committee Natera, Coordinating PI, Institutional, No financial interest

Pfizer, Coordinating PI, Institutional, Financial interest

Roche, Coordinating PI, Institutional, Financial interest

More from Michail Ignatiadis

3:29
Facilitating translational research in clinical trials
Michail Ignatiadis • 14 Mar 2024
3:03
Immune-related adverse events in breast cancer patients taking ICIs
Michail Ignatiadis • 14 Mar 2024
5:09
Use of checkpoint inhibitors in breast cancer treatment
Michail Ignatiadis • 14 Mar 2024
1:53
The clinical use of ctDNA as a biomarker in TNBC
Michail Ignatiadis • 22 Nov 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals